160 related articles for article (PubMed ID: 37549531)
1. Italian nivolumab Expanded Access Programme in melanoma adjuvant setting: patient outcomes and safety profile.
Ascierto PA; Di Giacomo AM; Chiarion Sileni V; Queirolo P; Spagnolo F; De Galitiis F; Cognetti F; Mandalà M; Guidoboni M; Rinaldi G; Depenni R; Consoli F; Troiani T; Guida M; Marconcini R; Ferrucci PF; Strippoli S; Fava P; Merelli B; Simeone E; Di Guardo L; Giannarelli D; Maio M; Quaglino P; Del Vecchio M
Eur J Cancer; 2023 Sep; 191():113246. PubMed ID: 37549531
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Ascierto PA; Del Vecchio M; Mandalá M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Maio M; Middleton MR; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Lobo M; de Pril V; Loffredo J; Larkin J; Weber J
Lancet Oncol; 2020 Nov; 21(11):1465-1477. PubMed ID: 32961119
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial.
Zimmer L; Livingstone E; Hassel JC; Fluck M; Eigentler T; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kieker F; Dippel E; Rösch A; Simon JC; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2020 May; 395(10236):1558-1568. PubMed ID: 32416781
[TBL] [Abstract][Full Text] [Related]
4. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial.
Hodi FS; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Cowey CL; Lao CD; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Hill A; Hogg D; Marquez-Rodas I; Jiang J; Rizzo J; Larkin J; Wolchok JD
Lancet Oncol; 2018 Nov; 19(11):1480-1492. PubMed ID: 30361170
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
Weber JS; Schadendorf D; Del Vecchio M; Larkin J; Atkinson V; Schenker M; Pigozzo J; Gogas H; Dalle S; Meyer N; Ascierto PA; Sandhu S; Eigentler T; Gutzmer R; Hassel JC; Robert C; Carlino MS; Di Giacomo AM; Butler MO; Muñoz-Couselo E; Brown MP; Rutkowski P; Haydon A; Grob JJ; Schachter J; Queirolo P; de la Cruz-Merino L; van der Westhuizen A; Menzies AM; Re S; Bas T; de Pril V; Braverman J; Tenney DJ; Tang H; Long GV
J Clin Oncol; 2023 Jan; 41(3):517-527. PubMed ID: 36162037
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238.
Larkin J; Del Vecchio M; Mandalá M; Gogas H; Arance Fernandez AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Marquez-Rodas I; Butler MO; Di Giacomo AM; Middleton MR; Lutzky J; de la Cruz-Merino L; Arenberger P; Atkinson V; Hill AG; Fecher LA; Millward M; Nathan PD; Khushalani NI; Queirolo P; Ritchings C; Lobo M; Askelson M; Tang H; Dolfi S; Ascierto PA; Weber J
Clin Cancer Res; 2023 Sep; 29(17):3352-3361. PubMed ID: 37058595
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.
Larkin J; Weber J; Del Vecchio M; Gogas H; Arance AM; Dalle S; Cowey CL; Schenker M; Grob JJ; Chiarion-Sileni V; Márquez-Rodas I; Butler MO; Di Giacomo AM; Middleton MR; De la Cruz-Merino L; Arenberger P; Atkinson V; Hill A; Fecher LA; Millward M; Khushalani NI; Queirolo P; Long GV; Lobo M; Askelson M; Ascierto PA; Mandalá M
Eur J Cancer; 2022 Sep; 173():285-296. PubMed ID: 35964471
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
Livingstone E; Zimmer L; Hassel JC; Fluck M; Eigentler TK; Loquai C; Haferkamp S; Gutzmer R; Meier F; Mohr P; Hauschild A; Schilling B; Menzer C; Kiecker F; Dippel E; Roesch A; Ziemer M; Conrad B; Körner S; Windemuth-Kieselbach C; Schwarz L; Garbe C; Becker JC; Schadendorf D;
Lancet; 2022 Oct; 400(10358):1117-1129. PubMed ID: 36099927
[TBL] [Abstract][Full Text] [Related]
9. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.
Versluis JM; Menzies AM; Sikorska K; Rozeman EA; Saw RPM; van Houdt WJ; Eriksson H; Klop WMC; Ch'ng S; van Thienen JV; Mallo H; Gonzalez M; Torres Acosta A; Grijpink-Ongering LG; van der Wal A; Bruining A; van de Wiel BA; Scolyer RA; Haanen JBAG; Schumacher TN; van Akkooi ACJ; Long GV; Blank CU
Ann Oncol; 2023 Apr; 34(4):420-430. PubMed ID: 36681299
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
Wolchok JD; Chiarion-Sileni V; Gonzalez R; Grob JJ; Rutkowski P; Lao CD; Cowey CL; Schadendorf D; Wagstaff J; Dummer R; Ferrucci PF; Smylie M; Butler MO; Hill A; Márquez-Rodas I; Haanen JBAG; Guidoboni M; Maio M; Schöffski P; Carlino MS; Lebbé C; McArthur G; Ascierto PA; Daniels GA; Long GV; Bas T; Ritchings C; Larkin J; Hodi FS
J Clin Oncol; 2022 Jan; 40(2):127-137. PubMed ID: 34818112
[TBL] [Abstract][Full Text] [Related]
11. Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data.
Freeman M; Betts KA; Jiang S; Du EX; Gupte-Singh K; Lu Y; Rao S; Shoushtari AN
Adv Ther; 2019 Oct; 36(10):2783-2796. PubMed ID: 31440980
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.
Weber JS; Poretta T; Stwalley BD; Sakkal LA; Du EX; Wang T; Chen Y; Wang Y; Betts KA; Shoushtari AN
Cancer Immunol Immunother; 2023 Apr; 72(4):945-954. PubMed ID: 36197494
[TBL] [Abstract][Full Text] [Related]
13. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Hodi FS; Chesney J; Pavlick AC; Robert C; Grossmann KF; McDermott DF; Linette GP; Meyer N; Giguere JK; Agarwala SS; Shaheen M; Ernstoff MS; Minor DR; Salama AK; Taylor MH; Ott PA; Horak C; Gagnier P; Jiang J; Wolchok JD; Postow MA
Lancet Oncol; 2016 Nov; 17(11):1558-1568. PubMed ID: 27622997
[TBL] [Abstract][Full Text] [Related]
14. Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma.
Holmstroem RB; Pedersen S; Jurlander R; Madsen K; Donia M; Ruhlmann CH; Schmidt H; Haslund CA; Bastholt L; Svane IM; Ellebaek E
Eur J Cancer; 2024 May; 202():114023. PubMed ID: 38518533
[TBL] [Abstract][Full Text] [Related]
15. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.
Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU
Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251
[TBL] [Abstract][Full Text] [Related]
16. Indirect treatment comparison of nivolumab versus placebo as adjuvant treatment for resected melanoma.
Weber JS; Ascierto PA; Middleton MR; Hennicken D; Zoffoli R; Pieters A; Amadi A; Kupas K; Kotapati S; Moshyk A; Schadendorf D
Eur J Cancer; 2021 Nov; 158():225-233. PubMed ID: 34663559
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial.
Lebbé C; Meyer N; Mortier L; Marquez-Rodas I; Robert C; Rutkowski P; Menzies AM; Eigentler T; Ascierto PA; Smylie M; Schadendorf D; Ajaz M; Svane IM; Gonzalez R; Rollin L; Lord-Bessen J; Saci A; Grigoryeva E; Pigozzo J
J Clin Oncol; 2019 Apr; 37(11):867-875. PubMed ID: 30811280
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
Kirkwood JM; Del Vecchio M; Weber J; Hoeller C; Grob JJ; Mohr P; Loquai C; Dutriaux C; Chiarion-Sileni V; Mackiewicz J; Rutkowski P; Arenberger P; Quereux G; Meniawy TM; Ascierto PA; Menzies AM; Durani P; Lobo M; Campigotto F; Gastman B; Long GV
Nat Med; 2023 Nov; 29(11):2835-2843. PubMed ID: 37845511
[TBL] [Abstract][Full Text] [Related]
19. Indirect treatment comparison of nivolumab versus placebo for the adjuvant treatment of melanoma.
Hemstock M; Amadi A; Kupas K; Roskell N; Kotapati S; Gooden K; Middleton MR; Schadendorf D
Eur J Cancer; 2020 Jun; 132():176-186. PubMed ID: 32380428
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant Therapy of High-Risk (Stages IIC-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis.
Christofyllakis K; Pföhler C; Bewarder M; Müller CSL; Thurner L; Rixecker T; Vogt T; Stilgenbauer S; Yordanova K; Kaddu-Mulindwa D
Front Oncol; 2020; 10():637161. PubMed ID: 33680957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
